Magnesium Sulphate Versus Lidocaine for Control of Emergence Hypertension

Control of Emergence Hypertension After Craniotomy: Comparison Between the Efficacy of Magnesium Sulphate and Lidocaine Infusion (Randomized Controlled Study)

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03566329

Enrollment

Registered

2018-06-25

Start date

2018-07-10

Completion date

2019-12-31

Last updated

2019-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Craniotomy, Hypertension

Keywords

craniotomy- Emergence- hypertension

Brief summary

Post-craniotomy emergence hypertension is a common phenomenon that may predispose to development of intracranial hematoma and cerebral edema.The aim of this study is to compare the safety and efficacy of Mgso4 versus lidocaine infusion for control of emergence hypertension after craniotomy.

Interventions

DRUGMagnesium sulphate

Magnesium sulphate 50 mg/kg over 10 minutes loading followed by 15mg/kg/hr infusion. .

DRUGLidocaine Hydrochloride

lidocaine hydrochloride 1.5mg/kg loading followed by 2mg/kg/hr infusion

DRUGNormal saline

Normal saline infusion with the same rate of infusion as the study drugs

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* ASA physical status Ι or Π. * scheduled patients for brain tumor excision.

Exclusion criteria

* Hepatic, renal, cardiac, pulmonary, or endocrine impairment. * Signs of increased intracranial pressure or allergy to any of the used drugs.

Design outcomes

Primary

Measure	Time frame	Description
postcraniotomy emergence hypertension response to the study drugs	4hours	The number of the patients who have systolic blood pressure below 140 mmH during emergence of anesthesia after craniotomy for brain tumors in each group

Secondary

Measure	Time frame	Description
Recovery time	2 hours	Time till discharge from PACU
Incidence of side effects of the used drugs	4 hours	measure of safety

Countries

Egypt

Contacts

Primary ContactAhmed ELbadawy, MD

elbadawyahmed89@yahoo.com01064249076

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026